Skip to content
lifestyle.thedishh.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
NanoViricides
NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA
May 5, 2026
Deadly Measles Cases Accentuate the Need for a Treatment – NV-387 is Here to Help Patients and Control Spread, Says NanoViricides
May 3, 2026
Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides
May 2, 2026
NanoViricides Presenting at NIBA’s 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 – Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete
April 28, 2026
Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides
April 1, 2026
NanoViricides President Dr. Diwan Interviewed by Mission Matters’ Adam Torres
February 7, 2026
←
Previous Page
1
2